Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Detian Li

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Chinese Medical Journal|May 29, 2025
Long-term safety and effectiveness of roxadustat in Chinese patients with chronic kidney disease-associated anemia: The ROXSTAR registryXiaoying Du, Yaomin Wang, Haifeng Yu, et al.
Clinical Rheumatology|November 15, 2018
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trialMinfang Zhang, Chaojun Qi, Yan Zha, et al.
Plos One|October 4, 2011
GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in miceXu Yang, Shinji Kume, Yuki Tanaka, et al.
Annals of Medicine|December 17, 2020
A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infectionYing Li, Yousheng Yin, Xiaomei Peng, et al.
BMC Nephrology|December 11, 2019
Protocol for a prospective, cluster randomized trial to evaluate routine and deferred dialysis initiation (RADDI) in Chinese populationXinju Zhao, Pei Wang, Lining Wang, et al.
Rheumatology (Oxford, England)|March 11, 2021
Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II studyYanwei Lin, Xiaoxiang Chen, Huihua Ding, et al.
International Journal of Rheumatic Diseases|August 25, 2025
2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common ComorbiditiesChanggui Li, Mingshu Sun, Zhen Liu, et al.
BMJ Open|September 11, 2019
Assessment of dialysis initiation by a fuzzy mathematics equation (ADIFE): a study protocol for a randomised controlled trialJilin Chen, Ying Liu, Xiangmei Chen, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Chinese Medical Journal|May 29, 2025
Long-term safety and effectiveness of roxadustat in Chinese patients with chronic kidney disease-associated anemia: The ROXSTAR registryXiaoying Du, Yaomin Wang, Haifeng Yu, et al.
Clinical Rheumatology|November 15, 2018
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trialMinfang Zhang, Chaojun Qi, Yan Zha, et al.
Plos One|October 4, 2011
GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in miceXu Yang, Shinji Kume, Yuki Tanaka, et al.
Annals of Medicine|December 17, 2020
A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infectionYing Li, Yousheng Yin, Xiaomei Peng, et al.
BMC Nephrology|December 11, 2019
Protocol for a prospective, cluster randomized trial to evaluate routine and deferred dialysis initiation (RADDI) in Chinese populationXinju Zhao, Pei Wang, Lining Wang, et al.
Rheumatology (Oxford, England)|March 11, 2021
Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II studyYanwei Lin, Xiaoxiang Chen, Huihua Ding, et al.
International Journal of Rheumatic Diseases|August 25, 2025
2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common ComorbiditiesChanggui Li, Mingshu Sun, Zhen Liu, et al.
BMJ Open|September 11, 2019
Assessment of dialysis initiation by a fuzzy mathematics equation (ADIFE): a study protocol for a randomised controlled trialJilin Chen, Ying Liu, Xiangmei Chen, et al.
Pageof 7